Alentis TherapeuticsAustralian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to co-develop and co-commercialize lixudebart, an investigational antibody targeting claudin-1. CSL will pay Alentis $355 million upfront and the Swiss biotech is eligible for up to another $1.2 billion in commercial milestone payments. Once the drug reaches the market, global profits will be split 55% to CSL and 45% to Alentis. What is the deal all about?
ADVERTISEMENT